Jacobs Levy Equity Management Inc. Grows Stock Position in AnaptysBio, Inc. (NASDAQ:ANAB)

Jacobs Levy Equity Management Inc. grew its stake in shares of AnaptysBio, Inc. (NASDAQ:ANAB - Free Report) by 85.3% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 85,381 shares of the biotechnology company's stock after acquiring an additional 39,307 shares during the period. Jacobs Levy Equity Management Inc. owned 0.28% of AnaptysBio worth $1,130,000 at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in ANAB. JPMorgan Chase & Co. boosted its stake in AnaptysBio by 191.4% in the 3rd quarter. JPMorgan Chase & Co. now owns 33,744 shares of the biotechnology company's stock worth $1,130,000 after purchasing an additional 22,164 shares during the period. Victory Capital Management Inc. grew its stake in AnaptysBio by 41.0% during the fourth quarter. Victory Capital Management Inc. now owns 334,450 shares of the biotechnology company's stock valued at $4,428,000 after acquiring an additional 97,200 shares in the last quarter. Vanguard Group Inc. increased its holdings in AnaptysBio by 8.4% during the 4th quarter. Vanguard Group Inc. now owns 1,843,740 shares of the biotechnology company's stock worth $24,411,000 after acquiring an additional 143,584 shares during the period. Y Intercept Hong Kong Ltd purchased a new stake in AnaptysBio in the 4th quarter worth approximately $311,000. Finally, AlphaQuest LLC boosted its holdings in AnaptysBio by 1,891.5% in the 4th quarter. AlphaQuest LLC now owns 4,461 shares of the biotechnology company's stock valued at $59,000 after purchasing an additional 4,237 shares during the period.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on ANAB shares. Johnson Rice reiterated a "buy" rating on shares of AnaptysBio in a research report on Wednesday, March 26th. HC Wainwright reissued a "neutral" rating and set a $22.00 price objective on shares of AnaptysBio in a report on Tuesday, March 4th. Guggenheim raised their target price on shares of AnaptysBio from $52.00 to $54.00 and gave the company a "buy" rating in a research note on Tuesday, May 6th. JPMorgan Chase & Co. boosted their price target on shares of AnaptysBio from $36.00 to $42.00 and gave the stock an "overweight" rating in a research note on Wednesday, March 5th. Finally, Wolfe Research started coverage on shares of AnaptysBio in a research report on Tuesday, February 4th. They set an "outperform" rating and a $25.00 price objective on the stock. Four equities research analysts have rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $35.88.

AnaptysBio Stock Performance

NASDAQ ANAB traded up $0.63 on Tuesday, reaching $21.10. 470,433 shares of the stock traded hands, compared to its average volume of 600,170. AnaptysBio, Inc. has a 12 month low of $12.21 and a 12 month high of $41.31. The company has a fifty day moving average price of $19.03 and a 200-day moving average price of $18.23. The company has a market cap of $619.92 million, a price-to-earnings ratio of -3.47 and a beta of -0.20.

AnaptysBio (NASDAQ:ANAB - Get Free Report) last announced its earnings results on Monday, May 5th. The biotechnology company reported ($1.28) earnings per share for the quarter, beating the consensus estimate of ($1.30) by $0.02. The company had revenue of $27.77 million during the quarter, compared to the consensus estimate of $15.27 million. AnaptysBio had a negative net margin of 289.75% and a negative return on equity of 287.94%. As a group, research analysts anticipate that AnaptysBio, Inc. will post -6.08 earnings per share for the current fiscal year.

AnaptysBio declared that its Board of Directors has initiated a share buyback plan on Monday, March 24th that authorizes the company to buyback $75.00 million in outstanding shares. This buyback authorization authorizes the biotechnology company to buy up to 13.1% of its stock through open market purchases. Stock buyback plans are generally a sign that the company's management believes its stock is undervalued.

AnaptysBio Profile

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.